BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoarthritis Inhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis. Expression levels of the ROR2 ligand WNT5A were higher in human osteoarthritic cartilage than in healthy cartilage. In a mouse fibroblast...
BioCentury | Sep 30, 2020
Distillery Therapeutics

Islet-like organoids expressing PD-L1 for diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes Pancreatic islet-like organoids overexpressing PD-L1 and derived from human induced pluripotent stem cells (iPS cells) could be used to treat Type I diabetes. The organoids were generated by engineering human...
BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

Synthetic switches aim T cells at cells expressing antigen combos David Baker’s team at University of Washington’s Institute for Protein Design published a study in Science showing its synthetic protein switches can direct T cells...
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

Horizon raising cash after Tepezza beats sales estimate Shares of Horizon Therapeutics plc (NASDAQ:HZNP) rose 24% Wednesday, adding nearly $2.9 billion to the company’s market cap after a 2Q20 earnings report that showed that sales...
BioCentury | Jun 24, 2020

June 23 Quick Takes: Illumina selects first biotechs for U.K. accelerator; plus updates from the NASDAQ IPO queue, and venture rounds for Surrozen, Tara

Illumina launches U.K. accelerator campus Illumina Inc. (NASDAQ:ILMN) selected three companies to join the first cohort of its new Cambridge, U.K.-based accelerator, and four genomics start-ups for the eleventh funding cycle at its San Francisco...
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging...
BioCentury | Jan 4, 2020
Company News

Next act for BeiGene’s tislelizumab: a Leap deal for gastric cancer

Fresh off the approval of tislelizumab in China, BeiGene has partnered with Leap to pair the PD-1 inhibitor with the latter’s DKK1 inhibitor to create a combination therapy that could help treat cancers that don’t...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | Aug 8, 2019
Distillery Therapeutics

Activating WNT signaling to regenerate aged or damaged intestinal epithelium

DISEASE CATEGORY: Gastrointestinal INDICATION: Gastrointestinal Increasing WNT signaling through NOTUM inhibition or WNT3A supplementation could promote the regeneration of aged or damaged intestinal epithelia. Expression levels of the extracellular WNT inhibitor NOTUM were higher in...
Items per page:
1 - 10 of 234